Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H48O6 |
Molecular Weight | 516.7092 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C(O)=O
InChI
InChIKey=IECPWNUMDGFDKC-MZJAQBGESA-N
InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
Molecular Formula | C31H48O6 |
Molecular Weight | 516.7092 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21546624
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21546624
Fusidic acid is a anti-bacterial agent, initially isolated from Fusidium coccineum by Godtfredsen et al (Leo Pharma) in 1960. It is discussed that fusidic acid exerts its anti-microbial effect by inhibiting bacterial elongation factor G, thus suppressing the protein synthesis. Fusidic acid is widely used in Europe under the names Fucidin H(fusidic acid / hydrocortisone acetate), Fucidin (fusidic acid / sodium fusidate) and Fucicort (fusidic acid / betamethasone valerate) for the treatment of primary/secondary skin infections and inflammatory dermatoses.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8475801
Curator's Comment: CNS penetration is low.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Bacterial elongation factor G |
1.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | FUCIDIN Approved UseFor use in the treatment of primary and secondary skin infections caused by sensitive strains of Staphylococcus aureus, Streptococcusspp and Corynebacterium minutissimum. Primary skin infections that may be expected to respond to treatment with FUCIDIN OINTMENT (sodium fusidate) and CREAM (fusidic acid) include: impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds and infected burns. |
|||
Curative | FUCICORT Approved UseFUCICORT is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, seborrheic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus |
PubMed
Title | Date | PubMed |
---|---|---|
Adverse reactions to intravenous administration of fusidic acid. | 1981 |
|
Screening for new compounds with antiherpes activity. | 1984 Oct |
|
Susceptibility of mycobacteria to fusidic acid. | 1990 Apr |
|
Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp. | 1990 Sep |
|
Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. | 1992 Aug |
|
Acute renal failure in association with fusidic acid. | 1997 Jun |
|
In vitro susceptibility of Mycobacterium tuberculosis to fusidic acid. | 2001 Dec |
|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | 2010 Dec |
|
Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid. | 2010 Jun |
|
Canine ocular thelaziosis caused by Thelazia callipaeda in Portugal. | 2013 Jul |
Patents
Sample Use Guides
A small amount of fucidin ointment(sodium fusidate) or cream (fusidic acid) should be
applied to the lesion 3 or 4 times daily until favourable results are achieved. Futicort cream (fusidic acid / betamethasone valerate) is applied 2 times daily.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21546624
In vitro fusidic acid inhibited S. aureus (minimum inhibitory concentration [MIC], 0.25 ug/mL), Micrococcus luteus (MIC, 0.25–0.5 ug/mL), Corynebacterium spp. (MIC, 0.06–0.12 ug/mL), Moraxella catarrhalis (MIC, 0.06–0.12 ug/mL), and Neisseria meningitidis (MIC, 0.12–0.25 ug/mL).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:00:13 GMT 2023
by
admin
on
Fri Dec 15 15:00:13 GMT 2023
|
Record UNII |
59XE10C19C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD09AA02
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
||
|
WHO-ATC |
D09AA02
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
||
|
WHO-ATC |
S01AA13
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
||
|
WHO-VATC |
QD06AX01
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
||
|
WHO-ATC |
D06AX01
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
||
|
WHO-VATC |
QS01AA13
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
||
|
NCI_THESAURUS |
C52588
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
||
|
WHO-VATC |
QJ01XC01
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
||
|
WHO-ATC |
J01XC01
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
113608
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
ALTERNATIVE | |||
|
71321
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
29013
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
1261
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
SUB02292MIG
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
3000226
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
PRIMARY | |||
|
1431
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
Fusidic Acid
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
59XE10C19C
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
230-256-0
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
D005672
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
PRIMARY | |||
|
56192
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
PRIMARY | |||
|
FUSIDIC ACID
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
PRIMARY | |||
|
4608
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL374975
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
DB02703
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
59XE10C19C
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
6990-06-3
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
SUB90515
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
m5616
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID0023086
Created by
admin on Fri Dec 15 15:00:13 GMT 2023 , Edited by admin on Fri Dec 15 15:00:13 GMT 2023
|
PRIMARY | |||
|
C65793
Created by
admin on Fri Dec 15 15:00:14 GMT 2023 , Edited by admin on Fri Dec 15 15:00:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |